Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
54-92-2
Molecular formula
C9H13N3O
Molecular weight
179.22 g/mol
Drug class
Hydrazine-derived monoamine oxidase inhibitor (MAOI)historical antidepressant and antitubercular agent
Mechanism of action
Irreversibly inhibits monoamine oxidase, reducing breakdown of serotonin, noradrenaline and dopamine and increasing monoaminergic neurotransmission. The same non-selective MAO inhibition contributes to clinically significant interactions and toxicity.
Indications / reported uses
Historically introduced for treatment of depressive illness and originally used as an antitubercular agent. It is no longer a routine contemporary antidepressant because of serious hepatotoxicity and other safety concerns; this entry is historical pharmacology, not a current treatment recommendation.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Iproniazid PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Iproniazid Permitted Daily Exposure (PDE) report (the Iproniazid PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Iproniazid Occupational Exposure Limit (OEL) report (the Iproniazid OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.